Home > TNF-alpha & > Pomalidomide

Pomalidomide

泊马度胺,CC-4047

Pomalidomide能抑制LPS诱导的TNF-α释放，IC50为13 nM。

目录号
EY1041
EY1041
EY1041
EY1041
纯度
99.02%
99.02%
99.02%
99.02%
规格
5 mg
10 mg
50 mg
100 mg
原价
330
520
790
1020
售价
330
520
790
1020
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Pomalidomide is a second generation immunomodulator, TNF-α inhibitor with IC50 of 13 nM. It shows immunomodulator and anticancer effects.

  • 体外研究

  • 体内研究

    1% DMSO+30% polyethylene glycol+1% Tween 80

  • 激酶实验

  • 细胞实验

    2.5-40 μg/mL

  • 动物实验

    0.5 mg/kg 腹腔注射

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.
    [2] Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.Phase I trial of pomalidomide given for patients with advanced solid tumors.Cancer Chemother Pharmacol. 2012 Aug 9.
    [3] Quach H et al Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 Jan;24(1):22-32.
    [4] Zhu YX, Kortuem KM, Stewart AK.Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma.Leuk Lymphoma. 2012 Sep 11.

    分子式
    C13H11N3O4    		 分子量
    273.24    		 CAS号
    19171-19-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    55 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01177735 Multiple Myeloma Drug: Pomalidomide University of Arkansas|Celgene Corporation Phase 2 2011-10-01 2015-02-18
    NCT01324947 Multiple Myeloma Drug: pomalidomide Celgene Corporation Phase 3 2011-03-01 2016-10-28
    NCT01198067 Lymphoma|Myeloma Drug: Pomalidomide|Drug: Pomalidomide M.D. Anderson Cancer Center|Celgene Corporation Phase 1 2010-10-01 2016-11-28
    NCT00717522 Soft Tissue Sarcoma Drug: Pomalidomide Celgene Corporation|Celgene Phase 2 2008-08-01 2013-03-06
    NCT01053949 Multiple Myeloma Drug: Pomalidomide|Drug: Pomalidomide University Hospital, Lille|Celgene Corporation Phase 2 2009-10-01 2015-11-03
    NCT01997840 Multiple Myeloma Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone Acetylon Pharmaceuticals Incorporated Phase 1|Phase 2 2013-11-01 2016-10-17
    NCT01522547 Anemia, Sickle Cell Drug: pomalidomide Celgene Corporation|Celgene Phase 1 2007-08-01 2013-12-24
    NCT02164955 Multiple Myeloma Drug: IMNOVID Celgene 2014-06-01 2017-02-01
    NCT00949364 Myeloproliferative Neoplasms Drug: Pomalidomide University of Ulm Phase 2 2009-12-01 2013-09-09
    NCT02045017 Multiple Myeloma Drug: Pomalidomide and Dexamethasone Celgene Corporation Phase 2 2014-05-01 2016-09-12
    NCT01734928 Multiple Myeloma Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone Celgene Phase 3 2013-01-07 2017-02-28
    NCT01078974 Waldenstrom's Macroglobulinemia Drug: pomalidomide|Drug: dexamethasone|Drug: rituximab Steven P. Treon, MD, PhD|Celgene Corporation|Dana-Farber Cancer Institute Phase 1 2010-05-01 2016-06-13
    NCT01474330 Healthy Drug: Pomalidomide|Drug: Placebo Celgene Corporation Phase 1 2011-08-01 2016-03-25
    NCT01568294 Multiple Myeloma Drug: pomalidomide Celgene Corporation|Celgene Phase 1 2012-04-01 2015-08-19
    NCT01178281 Primary Myelofibrosis Drug: Pomalidomide 0.5 mg|Drug: Placebo Celgene Phase 3 2010-09-01 2017-02-01
    NCT01311687 Multiple Myeloma Drug: pomalidomide|Drug: dexamethasone Celgene Phase 3 2011-03-01 2017-01-19
    NCT01979276 Multiple Myeloma Drug: Romidepsin|Drug: pomalidomide|Drug: Dexamethasone Weill Medical College of Cornell University|Celgene Corporation Phase 1|Phase 2 2013-11-01 2017-02-07
    NCT02555839 Multiple Myeloma Drug: Pomalidomide|Drug: Dexamethasone Celgene 2015-03-01 2017-03-02
    NCT01541332 Multiple Myeloma Drug: Pomalidomide|Drug: Pegylated Liposomal Doxorubicin (PLD)|Drug: Dexamethasone Oncotherapeutics|Celgene Corporation Phase 1|Phase 2 2012-02-01 2016-03-08
    NCT00946270 Polycythemia Vera|Thrombocythemia Drug: CC-4047|Drug: Prednisone M.D. Anderson Cancer Center|Celgene Phase 2 2009-07-01 2016-11-14
    NCT01495598 Kaposi Sarcoma|Sarcoma, Kaposi Drug: Pomalidomide National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1|Phase 2 2011-12-09 2017-01-24
    NCT02011113 Multiple Myeloma Drug: Pomalidomide|Drug: Dexamethasone Celgene Corporation Phase 2 2013-12-01 2016-09-12

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：